Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Trends That Matter for Hereditary Angioedema

Posted by Matt Breese on Sep 14, 2017

Find me on:

new-blog-image-development.png

In our weekly Trends that Matter series, we provide engaging infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is advancements in Hereditary Angioedema (HAE) treatment.

The HAE therapeutic landscape is expanding rapidly. However, factors such as access, side effects, and cost still limit some patients from receiving treatment. All products are considered specialty drugs, and there is only one option for a self-administered product.

Many prescribers are finding solace in recent advancements in HAE treatment which provide an option for pediatric patients suffering from this condition. This development is especially impactful because children have a 50% chance of inheriting HAE from one of their parents. 

According to Marc A. Riedl, MD, MS in Medscape's Education Allergy & Clinical Immunology Publication:

"The recent availability of new prophylactic and acute treatment options provides the potential opportunity for individualized HAE therapy determined by factors, including variability in response, tolerability, cost, and long-term safety."

Download MMIT's Reality Check on Hereditary Angioedema to read a full report on HAE with key findings on clinical characteristics. 


Subscribe to the MMIT blog for more insights on trends affecting pharmaceutical manufacturers, providers and payers.

Subscribe for Weekly Trends that Matter

Topics: Specialty